Funding
Planned strategic investment · Biotech

NVIDIA plans investment in biomolecular AI company Boltz

Boltz develops models and software for molecular design and drug-discovery workflows.

By RoundOS Funding desk

Planned strategic investment

NVIDIA announced a planned investment in Boltz on October 13, 2026. The amount and closing date were not disclosed.

Boltz provides foundation models, an API and a research platform for designing proteins and small molecules. On October 21, it separately announced an agreement with Bristol Myers Squibb to deploy its platform and co-develop custom models on the pharmaceutical company’s NVIDIA DGX SuperPOD infrastructure. That agreement builds on BMS scientists’ existing use of Boltz’s open-source models.

Funding history

Planned strategic investment · This roundUndisclosed

Sources

  1. blogs.nvidia.com
  2. boltz.com
  3. boltz.com

Similar rounds

All Biotech rounds →
Warp Sciences

Warp Sciences combines chemistry, AI and robotics to help drug discovery teams make and test molecules in the United States.

$215MSeries A · Oct 22, 2026
ugo

ugo develops service robots and software for security patrols, inspections and other work in physical environments.

¥1BDebt financing · Oct 21, 2026
theQA

A consumer research platform connecting organisations with local survey participants in Kuwait.

>$550KPre-seed · Oct 21, 2026
Pigment

Pigment provides business planning and performance-management software.

$250MSeries E · Oct 21, 2026

Related